This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Best Endovascular vs. Best Surgical Therapy in Patients With Critical Limb Ischemia (BEST-CLI)

This study is currently recruiting participants.
See Contacts and Locations
Verified May 2017 by New England Research Institutes
Sponsor:
Collaborators:
Brigham and Women's Hospital
Massachusetts General Hospital
Boston Medical Center
National Heart, Lung, and Blood Institute (NHLBI)
Information provided by (Responsible Party):
New England Research Institutes
ClinicalTrials.gov Identifier:
NCT02060630
First received: February 6, 2014
Last updated: June 20, 2017
Last verified: May 2017
February 6, 2014
June 20, 2017
August 2014
December 2019   (Final data collection date for primary outcome measure)
  • Time to major adverse limb event or death, whichever occurs first in subjects with Single-Segment Great Saphenous Vein (SSGSV) available [ Time Frame: Through each subject's last regularly scheduled study visit, up to a maximum of 50 months per subject ]
  • Time to major adverse limb event or death, whichever occurs first in subjects without available SSGSV [ Time Frame: Through each subject's last regularly scheduled study visit, up to a maximum of 50 months per subject ]
Major Adverse Limb Event (MALE) [ Time Frame: At 48 months ]
Complete list of historical versions of study NCT02060630 on ClinicalTrials.gov Archive Site
  • Time to re-intervention of the index leg, amputation of the index leg, or death, whichever occurs first in subjects with SSGSV available [ Time Frame: Through each subject's last regularly scheduled study visit, up to a maximum of 50 months per subject ]
  • Time to re-intervention of the index leg, amputation of the index leg, or death, whichever occurs first in subjects without available SSGSV [ Time Frame: Through each subject's last regularly scheduled study visit, up to a maximum of 50 months per subject ]
  • Number of re-interventions in the index leg in subjects with SSGSV available [ Time Frame: Through each subject's last regularly scheduled study visit, up to a maximum of 50 months per subject ]
  • Number of re-interventions in the index leg in subjects without available SSGSV [ Time Frame: Through each subject's last regularly scheduled study visit, up to a maximum of 50 months per subject ]
  • Time to all-cause mortality in subjects with SSGSV available [ Time Frame: Through each subject's last regularly scheduled study visit, up to a maximum of 50 months per subject ]
  • Time to all-cause mortality in subjects without available SSGSV [ Time Frame: Through each subject's last regularly scheduled study visit, up to a maximum of 50 months per subject ]
  • Change in VascuQoL score in subjects with SSGSV available [ Time Frame: 30 days post-procedure, 3 months, 12 months, 24 months, 36 months, and 48 months ]
  • Change in VascuQoL score in subjects without available SSGSV [ Time Frame: 30 days post-procedure, 3 months, 12 months, 24 months, 36 months, and 48 months ]
  • Change in EuroQoL EQ-5D score in subjects with SSGSV available [ Time Frame: 30 days post-procedure, 3 months, 12 months, 24 months, 36 months, and 48 months ]
  • Change in EuroQoL EQ-5D score in subjects without available SSGSV [ Time Frame: 30 days post-procedure, 3 months, 12 months, 24 months, 36 months, and 48 months ]
  • Treatment associated costs in subjects with SSGSV available [ Time Frame: Through each subject's last regularly scheduled study visit, up to a maximum of 50 months per subject ]
  • Treatment associated costs in subjects without available SSGSV [ Time Frame: Through each subject's last regularly scheduled study visit, up to a maximum of 50 months per subject ]
  • Major adverse cardiovascular events in subjects with SSGSV available [ Time Frame: 30 days post-procedure ]
  • Major adverse cardiovascular events in subjects without available SSGSV [ Time Frame: 30 days post-procedure ]
  • Proportion of subjects with at least one peri-operative complication in subjects with SSGSV available [ Time Frame: 30 days post-procedure ]
  • Proportion of subjects with at least one peri-operative complication in subjects without available SSGSV [ Time Frame: 30 days post-procedure ]
  • Clinical status [ Time Frame: 30 days, 3, 6, 12, 18 and 24 months (30, 36, 42 and 48 months for subjects enrolled early in the trial) ]
    Clinical status will be determined by assessing amputation status, myocardial infarction status, stroke status, secondary intervention (major or minor) status in index leg, number of interventions (major and minor) per limb salvaged, hemodynamic failure status, and clinical failure status.
  • Quality of life [ Time Frame: 30 days, 3, 12, and 24 months (36 and 48 months for subjects enrolled early in the trial) ]
    Quality of life (QoL) assessments will be determined by using the VascuQoL, EuroQoL EQ-5D, SF-12 and (at selected sites) the six-minute walk test.
  • Cost-Effectiveness Status [ Time Frame: 30 days, 3, 6, 12, 18 and 24 months (30, 36, 42 and 48 months for subjects enrolled early in the trial) ]
    Treatment-associated costs (in- and out-patient) and incremental cost-effectiveness measured in dollars per quality-adjusted life years.
  • Major adverse limb event [ Time Frame: 30 days ]
    Composite of major adverse limb event (MALE)
  • Pain status [ Time Frame: 30 days, 3, 6, 12, 18 and 24 months (36 and 48 months for those enrolled early in the trial) ]
    Numeric rating scale (NRS) for pain
  • Perioperative death [ Time Frame: 30 days ]
    Composite of perioperative death (POD) (death within 30 days of index procedure)
Not Provided
Not Provided
 
Best Endovascular vs. Best Surgical Therapy in Patients With Critical Limb Ischemia
Best Endovascular Versus Best Surgical Therapy in Patients With Critical Limb Ischemia
This study will compare the effectiveness of best available surgical treatment with best available endovascular treatment in adults with critical limb ischemia (CLI) who are eligible for both treatment options.
Male and female subjects aged 18 years or older will be randomized to receive either open surgical treatment or endovascular treatment. They will be followed for at least 2 years and up to 4 years and 2 months after treatment to primarily assess survival and major adverse limb events in the index or treated limb, and secondarily, to determine clinical and cost effectiveness outcomes after treatment. These outcomes (survival-free of major limb events and clinical, functional and cost effectiveness) will be compared within two cohorts of subjects: those with an available single-segment great saphenous vein, and those with an alternative conduit. The null hypotheses for both cohorts is that there will be no difference in MALE-free survival between best endovascular therapy and best surgical therapy.
Interventional
Not Provided
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Critical Limb Ischemia
  • Procedure: Open surgical revascularization
  • Device: Endovascular revascularization
    A variety of FDA approved devices will be used within this treatment arm. The trial will submit a proof-of-concept IDE application to the FDA to cover all devices.
  • Available vein, open surg. revasc.
    Subjects with an available SSGSV cohort randomized to open surgical revascularization
    Intervention: Procedure: Open surgical revascularization
  • Available vein, endovasc. revasc.
    Subjects with an available SSGSV cohort randomized to endovascular revascularization
    Intervention: Device: Endovascular revascularization
  • Alternative conduit, open surg. revasc.
    Subjects with an alternative conduit cohort randomized to open surgical revascularization
    Intervention: Procedure: Open surgical revascularization
  • Alternative conduit, endovasc. revasc.
    Subjects with an alternative conduit cohort randomized to endovascular revascularization
    Intervention: Device: Endovascular revascularization
Menard MT, Farber A, Assmann SF, Choudhry NK, Conte MS, Creager MA, Dake MD, Jaff MR, Kaufman JA, Powell RJ, Reid DM, Siami FS, Sopko G, White CJ, Rosenfield K. Design and Rationale of the Best Endovascular Versus Best Surgical Therapy for Patients With Critical Limb Ischemia (BEST-CLI) Trial. J Am Heart Assoc. 2016 Jul 8;5(7). pii: e003219. doi: 10.1161/JAHA.116.003219.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
2100
December 2019
December 2019   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Male or female, age 18 years or older.
  2. Infrainguinal PAOD (occlusive disease of the arteries below the inguinal ligament).
  3. CLI, defined as arterial insufficiency with gangrene, non-healing ischemic ulcer, or rest pain consistent with Rutherford categories 4-6.
  4. Candidate for both endovascular and open infrainguinal revascularization as judged by the treating investigators
  5. Adequate aortoiliac inflow.
  6. Adequate popliteal, tibial or pedal revascularization target defined as an infrainguinal arterial segment distal to the area of stenosis/occlusion which can support a distal anastomosis of a surgical bypass.
  7. Willingness to comply with protocol, attend follow-up appointments, complete all study assessments, and provide written informed consent.

Exclusion Criteria:

  1. Presence of a popliteal aneurysm (>2 cm) in the index limb.
  2. Life expectancy of less than 2 years due to reasons other than PAOD.
  3. Excessive risk for surgical bypass (as determined by the operating surgeon and the CLI Team)
  4. Planned above ankle amputation on ipsilateral limb within 4 weeks of index procedure.
  5. Active vasculitis, Buerger's disease, or acute limb-threatening ischemia
  6. Any prior index limb infrainguinal stenting or stent grafting associated with significant restenosis within 1 cm of stent or stent-graft, unless the occlusion/restenosis site is outside the intended treatment zone (i.e.,. a tibial vessel that is not currently intended to be revascularized as a part of the treatment for CLI).
  7. Any of the following procedures performed on the index limb within 3 months prior to enrollment:

    1. Infrainguinal balloon angioplasty, atherectomy, stent, or stentgraft;
    2. Infrainguinal bypass with either venous or prosthetic conduit
  8. Open surgical inflow procedure (aortofemoral, axillofemoral, iliofemoral, thoracofemoral or femorofemoral bypass) within 6 weeks prior to enrollment
  9. Current chemotherapy or radiation therapy.
  10. Absolute contraindication to iodinated contrast due to prior near-fatal anaphylactoid reaction (laryngospasm, bronchospasm, cardiorespiratory collapse, or equivalent) which would preclude patient participation in angiographic procedures.
  11. Pregnancy or lactation.
  12. Administration of an investigational drug for PAD within 30 days of randomization.
  13. Participation in a clinical trial (except observational studies) within the previous 30 days.
  14. Prior enrollment or randomization into BEST-CLI.
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact: Flora S Siami, MPH 617-972-3317 ssiami@neriscience.com
Canada,   United States
 
 
NCT02060630
BEST-CLI Trial
1U01HL107407 ( U.S. NIH Grant/Contract )
Yes
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Device Product Not Approved or Cleared by U.S. FDA: No
Pediatric Postmarket Surveillance of a Device Product: No
Plan to Share IPD: No
New England Research Institutes
New England Research Institutes
  • Brigham and Women's Hospital
  • Massachusetts General Hospital
  • Boston Medical Center
  • National Heart, Lung, and Blood Institute (NHLBI)
Principal Investigator: Matthew Menard, MD Brigham and Women's Hospital
Principal Investigator: Alik Farber, MD Boston University
Principal Investigator: Kenneth Rosenfield, MD Massachusetts General Hospital
Principal Investigator: Flora S Siami, MPH New England Research Institutes, Inc.
Principal Investigator: Susan Assmann, PhD New England Research Institutes, Inc.
New England Research Institutes
May 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP